[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

914-860-6855

Email address

reynold.daniel@veronapharma.com

Condition

COPD

Treatment type

Interventional

Investigational product

Ensifentrine 1000mcg

Phase

Phase 2

Sponsor

Verona Pharma plc

ClinicalTrials.gov identifier

NCT04091360

Study number

RPL554-MD-201

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

The purpose of this study is to find the best dose of RPL554 for treating the symptoms of COPD. COPD is a progressive disease that effects the lungs. In this study single doses will be given in the Part A of the study. The information from Part A will be used to decide the best doses to be used in Part B. In this part, patients will take 4-5 different doses, each for a week to decide which dose best treats the symptoms of COPD.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria
  1. Male and female patients with moderate to severe COPD, with a post bronchodilator FEV1 of 40 to 80% of predicted and FEV1/FVC ratio of ≤0.70.
  2. They must have a baseline increase in FEV1 of >150 mL following four puffs of salbutamol.
  3. They must have at least a 10 pack-year smoking history, and may be either a current or former smoker.
Exclusion criteria
  1. Patients must be clinically stable without recent COPD exacerbations or hospitalisations.
  2. They must not have uncontrolled disease or chronic heart failure.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site